# US 7,411,042 B2 · Tumor associated nucleic acids and uses therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,411,042 B2
- Document ID: US7411042B2
- Status: Granted
- Kind: B2
- Application number: 11/240,341
- Filed: 2005-09-30
- Published: 2006-02-02
- Granted: 2008-08-12
- Earliest claimed: 1998-04-15
- Assignees: Ludwig Institute for Cancer Research
- Inventors: Valérie Martelange; Charles De Smet; Thierry Boon-Falleur
- Web page: https://patentgrep.com/patent/US7411042B2

## CPC

- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- A61K 40/46: Viral antigens
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention describes SAGE (sdph3.10) and sdp3.5 tumor associated nucleic acids, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acid molecules, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a sdph3.10 and/or sdp3.5 gene product.

## Claims

### Claim 1

An isolated polypeptide comprising the amino acid sequence set forth as SEQ ID NO: 39 or SEQ ID NO:44, wherein the polypeptide is immunogenic.

### Claim 2 (depends on 1)

A composition comprising the isolated polypeptide of claim 1 and a pharmaceutical carrier.

### Claim 3 (depends on 2)

The composition of claim 2, further comprising an adjuvant.

### Claim 4 (depends on 1)

An isolated fusion protein comprising the polypeptide of claim 1.

### Claim 5 (depends on 4)

A composition comprising the isolated fusion protein of claim 4 and a pharmaceutical carrier.

### Claim 6 (depends on 5)

The composition of claim 5, further comprising an adjuvant.